Semi compliant / Polyamide balloon: | Precise & Predictable balloon growth |
Hydrophilic Coating: | On the distal shaft |
Stent Platform : | Co-Cr stent closed designed for unique platform |
Radio opaque markers: | Zero Profile |
Maximum recommended guidewire / Tip entry profile: | 0.014 “(0.36mm) / 0.017 “(0.43mm)
|
Excellent deflation time: | Average less than 10 sec |
Shaft Diameter: | Proximal 1.95F (0.64mm), |
Distal 2.7F (0.89mm) | |
Guiding catheter compatibility: | 5F (min ID 0.056″) |
Catheter Length: | 140cm |
Rapid Exchange Length: | 25 cm |
Radio opaque visual markers: | 90cm & 100cm |
Rated burst pressure: | Nominal pressure 8 ATM |
Rated burst pressure 16 ATM |
Design : | Laser cut closed cell |
Stent Material : | MP35N cobalt chromium alloy |
Stent Platform : | Co-Cr stent closed designed for unique platform |
Strut thickness/width: | 0.080mm / 0.075mm (SV) |
0.092mm/0.083mm (MV) | |
Metal to artery ratio: | 13.9 – 19.1% (SV)
|
11.4 – 15.2% (MV) | |
Average Foreshortening: | < 2% |
Average Recoil: | < 5% |
Average crossing profile: | < 1.0mm |
Drug: | Sirolimus (Rapamycin) |
Polymers Type: | Fully Biodegradable polymer |
SV = Small vessel stent | Total release of drug in 45 -48 days |
MV = Medium vessel stent | Total loading 161 ug in 3.0 x 19mm stent |
Pressure ATM / Balloon Diameter (mm) | 2.25 | 2.50 | 2.75 | 3.00 | 3.50 | 4.00 |
---|---|---|---|---|---|---|
2 | 1.96 | 2.21 | 2.46 | 2.71 | 3.21 | 3.71 |
4 | 2.06 | 2.31 | 2.56 | 2.81 | 3.31 | 3.81 |
6 | 2.16 | 2.41 | 2.66 | 2.91 | 3.41 | 3.91 |
8 (Nominal) | 2.25 | 2.50 | 2.75 | 3.00 | 3.50 | 4.00 |
10 | 2.31 | 2.56 | 2.81 | 3.06 | 3.56 | 4.08 |
12 | 2.37 | 2.62 | 2.87 | 3.12 | 3.62 | 4.16 |
14 | 2.43 | 2.68 | 2.93 | 3.18 | 3.68 | 4.24 |
16 RBP | 2.49 | 2.74 | 2.99 | 3.24 | 3.74 | 4.30 |
18 | 2.52 | 2.78 | 3.03 | 3.29 | 3.80 | 4.36 |
20 | 2.55 | 2.82 | 3.07 | 3.34 | 3.86 | 4.42 |
Length (mm) / Diameter (mm) | 2.25 | 2.50 | 2.75 | 3.00 | 3.50 | 4.00 |
---|---|---|---|---|---|---|
8 mm | NMX22508 | MNX25008 | NMX27508 | |||
11 mm | NMX22511 | NMX25011 | NMX27511 | NMX30011 | NMX35011 | NMX40011 |
14 mm | NMX22514 | NMX25014 | NMX27514 | NMX30014 | NMX35014 | NMX40014 |
19 mm | NMX22519 | NMX25019 | NMX27519 | NMX30019 | NMX35019 | NMX40019 |
24 mm | NMX22524 | NMX25024 | NMX27524 | NMX30024 | NMX35024 | NMX40024 |
29 mm | NMX22529 | NMX25029 | NMX27529 | NMX35029 | NMX27511 | NMX40029 |
34 mm | NMX30034 | NMX35034 | NMX40034 | |||
39 mm | NMX30039 | NMX35039 | NMX40039 |
The stent design provides an excellent balance between delivery characteristic & performance after expansion
Uses clinically proven, safe and effective sirolimus drug eluting from biodegradable ploymetric matrix
100% drug in the base layer
Unique Technology
Co-Cr stent platform has propriety unique electro polishing technology, which enables unsurpassed surface finishing to ensure an excellent deliverability, Even scaffolding & outstanding radial strength in NOVA MATRIX
Proven drug release kinetics
NOVA MATRIX has proven drug release kinetics
Initial Burst Release of 40% – 50% sirolimus in the first week followed by susteined release upto 45-48 days to maintain therapeutic sirolimus drug concentration to optimise the antitissue proliferative action